Scientific Sessions 2024  /  Navigating the Mix of Meds and Lifestyle for Obesity Medicine  /  Obesity Pharmacotherapy – where are we now?
Logo

American Heart Association

  2
  0

Final ID:

Obesity Pharmacotherapy – where are we now?

  • Stanford, Fatima  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Kosiborod, Mikhail  ( ST LUKES HEALTH SYSTEM , Kansas City , Missouri , United States )
    • Author Disclosures:
    Fatima Stanford: DO have relevant financial relationships ; Consultant:Eli Lilly:Active (exists now) ; Advisor:Clearmind Medicine:Active (exists now) ; Consultant:Veri:Active (exists now) ; Consultant:Gelesis:Past (completed) ; Consultant:Rhythm:Past (completed) ; Advisor:Doximity:Active (exists now) ; Advisor:Empros Pharma:Active (exists now) ; Advisor:Life Force:Active (exists now) ; Advisor:Vida Health:Active (exists now) ; Advisor:Ilant Health:Active (exists now) ; Advisor:GoodRx:Active (exists now) ; Advisor:Calibrate:Active (exists now) ; Advisor:Sweetch:Active (exists now) ; Advisor:Melli Cell:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) | Mikhail Kosiborod: DO have relevant financial relationships ; Consultant:35Pharma, Imbria Pharmaceuticals:Active (exists now) ; Consultant:Esperion Therapeutics, Structure Therapeutics:Active (exists now) ; Consultant:Eli Lilly, scPharmaceuticals:Active (exists now) ; Consultant:Dexcom, Sanofi, Youngene Therapeutics:Active (exists now) ; Consultant:Cytokinetics, Regeneron:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now) ; Consultant:Bayer, Pharmacosmos:Active (exists now) ; Other (please indicate in the box next to the company name):AstraZeneca, Vifor Pharma - data analytic center fees:Active (exists now) ; Consultant:AstraZeneca, Pfizer, Vifor Pharma:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca, Pfizer:Active (exists now) ; Consultant:Arrowhead Pharmaceuticals:Active (exists now) ; Consultant:Applied Therapeutics:Active (exists now) ; Consultant:Amgen, NovoNordisk:Active (exists now) ; Consultant:Alnylam, Merck (Diabetes and Cardiovascular):Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Navigating the Mix of Meds and Lifestyle for Obesity Medicine

Sunday, 11/17/2024 , 03:30PM - 04:45PM

Cardiovascular Seminar

More abstracts on this topic:
Resources for the busy clinician: engaging your patient and addressing barriers to healthy lifestyle

Dennison Himmelfarb Cheryl, Durant Raegan, Rao Goutham

But There’s a Pill for That! What is the role of lifestyle in the era GLP-1s?

Ard Jamy, Davies Melanie, Neeland Ian

More abstracts from these authors:
Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial

Kosiborod Mikhail

The evolving therapeutic landscape in obesity and the effect on cardiovascular outcomes

Kosiborod Mikhail

You have to be authorized to contact abstract author. Please, Login
Not Available